Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04047940 | A Study of LY900020 in Healthy Chinese Participants | PHASE1 | COMPLETED | 32 | — | — | Nov 29, 2019 | Feb 18, 2020 | Mar 3, 2020 | 1 | Singapore |
PK: AUC of LY900020
PK: Cmax of LY900020
| Arm | Type | Description |
|---|---|---|
| LY900020 Formulation 1 | EXPERIMENTAL | LY900020 Formulation 1 administered orally |
| LY900020 Formulation 2 | EXPERIMENTAL | LY900020 Formulation 2 administered orally |
| LY900020 Formulation 3 | EXPERIMENTAL | LY900020 Formulation 3 administered orally |
| Reference Drugs | ACTIVE_COMPARATOR | Metformin XR, atorvastatin, and valsartan administered orally |
| Name | Type | Description |
|---|---|---|
| LY900020 | DRUG | Administered orally |
| Metformin XR | DRUG | Administered orally |
| Atorvastatin | DRUG | Administered orally |
| Valsartan | DRUG | Administered orally |
Inclusion Criteria: * Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion) * Have a body mass index (BMI) of 18.5 to 35 kilogram per square meter (kg/m²), inclusive, at screening * Have normal blood pressure, pulse rate, electrocardiogr...